Boston Scientific Rises on Trial Results
Shares climbed 5.6% after the company said its SIMPLAAFY trial met primary endpoints for WATCHMAN post-implant medications.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Would you invest in health-care stocks after a major company's shares dropped over half?
Boston Scientific stock rose 5.6% on November 2, 2026, while the S&P 500 fell 0.5%. The company announced that the SIMPLAAFY trial met its primary endpoints, showing patients on either of two single-drug options performed no worse at six months than those on two anti-platelet drugs.
Why it matters
The results support the potential to simplify drug regimens after WATCHMAN implantation. The company has faced pressure, with WATCHMAN U.S. sales down 7% from a year earlier in fiscal Q3 2026.
Boston Scientific's $44.32 close sits near its 52-week closing low of $41.58 set October 7, 2026, and the stock has lost 55.9% over the past twelve months. WATCHMAN U.S. sales fell 7% year over year in fiscal Q3 2026.
The players
Boston Scientific
A medical device company whose WATCHMAN device treats stroke risk in patients with atrial fibrillation, and which faces competitive pressure in the market.
Blackstone Life Sciences
The life sciences investment arm of the global asset manager Blackstone, which is co-funding development of VITALYST.
The details
Boston Scientific announced on November 2, 2026 that the SIMPLAAFY trial met its primary endpoints, evaluating post-implant medications for its WATCHMAN device. Blackstone Life Sciences separately announced a $455 million collaboration to co-fund development of VITALYST the same day.
Timeline
October 7, 2026: Boston Scientific stock set a 52-week closing low of $41.58.
October 28, 2026: Stock fell 5.8% following the earnings call.
November 2, 2026: SIMPLAAFY results announced and stock rose 5.6%.
February 2027: Boston Scientific expected to report fiscal fourth-quarter 2026 results.
Market Landscape
The WATCHMAN device competes in a market where Boston Scientific's U.S. sales have softened, prompting the company to pursue new indications and drug-regimen simplification. The results position the company to reduce reliance on multi-drug post-implant protocols.
Investors tracking medtech stocks should note the company's 55.9% twelve-month decline and its proximity to a 52-week low despite the trial-driven rally. The gain came on a day the broader market fell, which may reflect sensitivity to clinical news.
The takeaway
Clinical trial news can move medtech shares sharply even when a company faces broader sales headwinds. Readers following healthcare stocks should weigh trial milestones alongside recent revenue trends.
What happens next
Boston Scientific is expected to report its fiscal fourth-quarter 2026 results in February 2027.
Further reading
For broader context on drug-device developments, see Healthcare coverage in Boston.
Live Poll
Would you invest in health-care stocks after a major company's shares dropped over half?
